ValuEngine lowered shares of Agenus (NASDAQ:AGEN) from a sell rating to a strong sell rating in a research report report published on Friday, December 29th.
AGEN has been the subject of several other reports. Zacks Investment Research raised shares of Agenus from a hold rating to a buy rating and set a $4.25 price objective for the company in a research report on Wednesday, October 25th. BidaskClub cut shares of Agenus from a hold rating to a sell rating in a research report on Saturday, December 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $5.88.
Shares of Agenus (NASDAQ AGEN) opened at $3.87 on Friday. The company has a debt-to-equity ratio of -2.39, a current ratio of 1.55 and a quick ratio of 1.55. Agenus has a 1-year low of $3.20 and a 1-year high of $5.45. The firm has a market cap of $336.69, a P/E ratio of -3.31 and a beta of 2.11.
Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.37). The business had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $5.91 million. Agenus’s revenue was down 24.4% on a year-over-year basis. equities analysts expect that Agenus will post -1.16 earnings per share for the current fiscal year.
In related news, insider Karen Valentine sold 8,358 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $3.46, for a total transaction of $28,918.68. Following the sale, the insider now owns 109,879 shares of the company’s stock, valued at $380,181.34. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Garo H. Armen purchased 100,000 shares of Agenus stock in a transaction on Monday, October 30th. The stock was acquired at an average cost of $3.55 per share, for a total transaction of $355,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 20,514 shares of company stock worth $70,978. Company insiders own 7.90% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. TIAA CREF Investment Management LLC lifted its stake in shares of Agenus by 0.6% during the second quarter. TIAA CREF Investment Management LLC now owns 204,576 shares of the biotechnology company’s stock valued at $800,000 after buying an additional 1,283 shares during the period. The Manufacturers Life Insurance Company increased its position in Agenus by 6.7% during the second quarter. The Manufacturers Life Insurance Company now owns 63,595 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 4,006 shares during the last quarter. Voya Investment Management LLC increased its position in Agenus by 18.5% during the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 6,381 shares during the last quarter. Teachers Advisors LLC increased its position in Agenus by 9.7% during the second quarter. Teachers Advisors LLC now owns 141,776 shares of the biotechnology company’s stock worth $554,000 after purchasing an additional 12,509 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in Agenus by 6.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 282,015 shares of the biotechnology company’s stock worth $1,244,000 after purchasing an additional 16,470 shares during the last quarter. 37.87% of the stock is currently owned by institutional investors and hedge funds.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.